The 150-patient Phase III prospective study is being conducted at 10 centers throughout the US and expects to enroll its first patient by next month.

Study investigator Ava Shamban said Artefill is a great solution for my regular filler patients who want to correct facial wrinkles with natural, long-lasting results.

Suneva Medical chairman and CEO Nicholas Teti said they hope Artefill’s unique composition may provide the patients a real solution for what many thought would be a lifelong problem.

The long-lasting injectable product is marketed as Artefill in the US and Bellafill in Canada to correct facial wrinkles, the company said.

Suneva Medical is focused on developing, manufacturing and commercializing novel, differentiated aesthetic products for the dermatology, plastic and cosmetic surgery markets.